Last reviewed · How we verify

Docetaxel (DOC) — Competitive Intelligence Brief

Docetaxel (DOC) (Docetaxel (DOC)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane; microtubule stabilizer. Area: Oncology.

marketed Taxane; microtubule stabilizer β-tubulin Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Docetaxel (DOC) (Docetaxel (DOC)) — Sun Yat-sen University. Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Docetaxel (DOC) TARGET Docetaxel (DOC) Sun Yat-sen University marketed Taxane; microtubule stabilizer β-tubulin
Albendazole plus Praziquantel Albendazole plus Praziquantel Navrongo Health Research Centre, Ghana marketed Antihelmintic combination β-tubulin (albendazole); calcium channels (praziquantel)
albendazole and praziquantel albendazole and praziquantel R-Evolution Worldwide S.r.l. Impresa Sociale marketed Anthelmintic combination β-tubulin (albendazole); calcium channels (praziquantel)
Placebo plus Docetaxel Placebo plus Docetaxel Infinity Pharmaceuticals, Inc. marketed Taxane (microtubule stabilizer) Microtubules (β-tubulin)
VLI VLI Spectrum Pharmaceuticals, Inc marketed Vinca alkaloid β-tubulin
Standard of Care: Docetaxel Standard of Care: Docetaxel H. Lee Moffitt Cancer Center and Research Institute marketed Taxane; microtubule stabilizer β-tubulin
Paclitaxel (Pac) Paclitaxel (Pac) Aravive, Inc. marketed Taxane; microtubule stabilizer β-tubulin / microtubules

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane; microtubule stabilizer class)

  1. Sanofi · 2 drugs in this class
  2. Aravive, Inc. · 1 drug in this class
  3. Athenex, Inc. · 1 drug in this class
  4. Barts & The London NHS Trust · 1 drug in this class
  5. BeyondSpring Pharmaceuticals Inc. · 1 drug in this class
  6. Bio-Thera Solutions · 1 drug in this class
  7. Dai, Guanghai · 1 drug in this class
  8. Fujian Medical University · 1 drug in this class
  9. Guangzhou Double Bioproducts Co., Ltd · 1 drug in this class
  10. H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Docetaxel (DOC) — Competitive Intelligence Brief. https://druglandscape.com/ci/docetaxel-doc. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: